AMGN | tickerfilter.com

Fundamental analysis

62%

Profitability 93%

Dept financing 26%

Liquidity 10%

Performance 54%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.89%

1 Month

-12.26%

3 Months

0.90%

6 Months

-12.46%

1 Year

1.98%

2 Year

13.71%

Key data

Stock price

$277.29

P/E Ratio

33.98

DAY RANGE

$268.50 - $278.68

EPS

$7.62

52 WEEK RANGE

$253.30 - $346.85

52 WEEK CHANGE

$1.98

MARKET CAP

138.980 B

YIELD

3.48%

SHARES OUTSTANDING

537.329 M

DIVIDEND

$2.38

EX-DIVIDEND DATE

05-16-2025

NEXT EARNINGS DATE

05-01-2025

BETA

0.67

PUBLIC FLOAT

AVERAGE 10 VOLUME

$3,116,382

AVERAGE 30 VOLUME

$3,318,290

Company detail

CEO: Robert A. Bradway
Region: US
Website: amgen.com
Employees: 25,200
IPO year: 1984

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. Repatha reduces the risks of myocardial infarction, stroke, and coronary revascularization.

AMGN - AMGEN INC